MANGOCEUTICALS, INC. MGRX
information included in this Report on Form 10-K should be read in conjunction with the consolidated financial statements and related
notes in "Item 8. Financial Statements and Supplemental Data" of this Report.
logo and some of our trademarks and tradenames are used in this Report. This Report also includes trademarks, tradenames and service
marks that are the property of others. Solely for convenience, trademarks, tradenames, and service marks referred to in this Report may
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $456.0K | $615.9K | $731.5K | $8.9K | — |
| Cost of revenue | $54.4K | $93.3K | $154.9K | $4.1K | — |
| Gross profit | $250.4K | $380.0K | $431.5K | $4.8K | — |
| SG&A | $3.8M | $3.0M | $3.3M | $1.6M | — |
| Total operating expenses | $18.3M | $8.4M | $9.7M | $2.0M | — |
| Operating income | -$18.0M | -$8.0M | -$9.2M | -$2.0M | — |
| Interest expense | $103.5K | $13.7K | $6.5K | $6.5K | — |
| Pre-tax income | -$20.6M | -$8.7M | -$9.2M | -$2.0M | — |
| Net income | -$20.6M | -$8.7M | -$9.2M | -$2.0M | — |
| EPS, basic | -2.17 | -4.80 | -8.58 | -0.19 | — |
| EPS, diluted | -2.17 | -4.80 | -8.58 | -0.19 | — |
| Shares, diluted (wtd. avg.) | 10.1M | 2.0M | 1.1M | 10.8M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $1.5M | $58.7K | $739.0K | $682.9K | — |
| Inventory | — | — | $18.5K | — | — |
| Total current assets | $1.5M | $75.6K | $835.4K | $694.6K | — |
| Property, plant and equipment | $1.8K | $2.8K | $96.1K | $117.5K | — |
| Other intangibles | $14.2M | $15.2M | — | — | — |
| Total assets | $16.1M | $15.4M | $1.1M | $1.0M | — |
| Accounts payable | $416.7K | $837.5K | $140.8K | $33.7K | — |
| Total current liabilities | $890.6K | $1.4M | $211.1K | $260.6K | — |
| Total liabilities | $890.6K | $1.4M | $276.0K | $389.3K | — |
| Retained earnings | -$40.6M | -$20.0M | -$11.2M | -$2.0M | — |
| Total equity | $15.2M | $13.9M | $774.8K | $614.0K | -$16.7K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$5.9M | -$4.9M | -$7.0M | -$1.3M | — |
| Depreciation and amortisation | $1.0K | $9.9K | $24.9K | $3.9K | — |
| Stock-based compensation | $1.2M | $248.7K | $624.5K | $234.1K | — |
| Capital expenditure | — | — | $3.5K | $43.1K | — |
| Investing cash flow | — | $65.0K | -$3.5K | -$43.1K | — |
| Financing cash flow | $7.3M | $4.1M | $7.1M | $2.0M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-014478.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $8.9K | $731.5K | $615.9K | $456.0K |
| Gross profit | — | $4.8K | $431.5K | $380.0K | $250.4K |
| Net income | — | -$2.0M | -$9.2M | -$8.7M | -$20.6M |
Recent filings and events
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Officer or director change Item 5.02
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8090
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| DVA | DAVITA INC. | $11.72B | 18.7x | 6.5% |
| SHC | Sotera Health Co | $5.17B | 67.0x | 5.7% |
| PGNY | Progyny, Inc. | $2.22B | 44.6x | 10.4% |
| AGL | agilon health, inc. | $1.51B | — | -2.1% |
| VMD | VIEMED HEALTHCARE, INC. | $373.3M | 26.5x | 20.5% |
| BRTX | BioRestorative Therapies, Inc. | $41.3M | — | -10.3% |
| CCEL | CRYO CELL INTERNATIONAL INC | $35.9M | — | -1.3% |
| FMS | Fresenius Medical Care AG | — | — | — |